prostate cancer, albeit controversial, include staging of intermediate and high-risk cases to evaluate for visibility of tumor, extraprostatic extension, and involvement ofseminal vesiclesor lymph nodes.119–121The NCCN guidelines recommend “pelvic CT or MR imaging if T3, T4 or T1-T2 and nomogram...
Lymphatic spread determines treatment decisions in prostate cancer (PCa) patients. 68Ga-PSMA-PET/CT can be performed, although cost remains high and availability is limited. Therefore, computed tomography (CT) continues to be the most used modality for PCa staging. We assessed if convolutional neur...
Variations in the Use of Prostate Cancer Staging Tests: Results From One NCCN Institutiondoi:10.1016/S0022-5347(01)62622-3C.L. Bennett and T. Yang and R. NadlerThe Journal of Urology
Our objective was to validate and compare prediction models selecting newly diagnosed prostate cancer patients for bone scan staging. To achieve this, we validated eleven models in a population-based cohort of 10,721 patients diagnosed with prostate cancer between 2005 and 2019. The primary outcome ...
We analyzed diagnostic performance in predicting bone metastasis of the guidelines of the European Association of Urology (EAU), American Urological Association (AUA), and the National Comprehensive Cancer Network (NCCN) guidelines as well as Briganti's classification and regression tree (CART). We ...
Prostate cancer is a complex disease that affects millions of men globally, predominantly in high human development index regions. Patients with localized disease at a low to intermediate risk of recurrence generally have a favourable outcome of 99% over
NCCN clinical practice guidelines in oncology: prostate cancer. Clinical practice guidelines limited to early detection, screening, staging and/or diagnosis of prostate cancer were excluded from analysis. Four independent ... J Mohler,RJ Babaian,RR Bahnson,... - 《Journal of Urology》 被引量: ...
NCCN: National Comprehensive Cancer Network MMR: DNA mismatch repair PARP: Poly(ADP‐ribose) polymerase (PARP) PD-1: Programmed Cell Death (receptor) PD-L1: Programmed Cell Death Ligand 1 PTEN: Phosphatase and tensin homolog SCT-NOS: Sertoli cell tumor, not otherwise specified TGCT:...
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castrati...
Shead, MS NCCN Guidelines Panel Disclosures NCCN Prostate Cancer Panel Members Summary of Guidelines Updates Initial Prostate Cancer Diagnosis (PROS-1) Initial Risk Stratification and Staging Workup for Clinically Localized Disease (PROS-2) Very-Low-Risk Group (PROS-3) Low-Risk Group (PROS-4) ...